Objective To observe the clinical efficacy of ebastine combined with hydroxychloroquine in the treatment of facial corticosteroid dependent dermatitis. Methods A total od 62 patients with facial corticosteroid dependent dermatitis treated in our hospital from January 2020 to January 2021 were randomly divided into control group and observation group, with 31 cases in each group. The control group was treated with ebastine, and the observation group was treated with hydroxychloroquine on the basis of the control group. The clinical efficacy, lesion area at different time points, clinical symptom score, skin function index and incidence of adverse reactions were compared between the two groups. Results The total effective rate of the observation group (90.32%) was higher than that of the control group (80.65%) (P＜0.05). After 2 weeks of treatment, the lesion area of the observation group was smaller than that of the control group (P＜0.05); however, there was no significant difference between the two groups after 1 week of treatment (P＞0.05). The scores of itching, burning, drying, pain and tension in the observation group were lower than those in the control group (P＜0.05). The skin lipid levels in the two groups were higher than those before treatment, and the percutaneous water loss value and skin erythema volume were lower than those before treatment, and the skin lipid level in the observation group was higher than that in the control group, and the percutaneous water loss value and skin erythema volume were lower than those in the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the observation group (6.45%) and the control group (9.68%) (P＞0.05). Conclusion Ebastine combined with hydroxychloroquine is effective in the treatment of facial corticosteroid dependent dermatitis, which can improve the total effective rate, reduce the lesion area, reduce the clinical symptom score, and improve the skin function index. It is a safe and effective treatment scheme.